Login / Signup

Chimeric antigen receptor T-cell (CART) therapy in non-Hodgkin's lymphoma: the survival gain improves as more mature follow-up data become available.

Andrea MessoriLaura BartoliDaniele MengatoMarco Chiumente
Published in: European journal of hospital pharmacy : science and practice (2020)
Keyphrases
  • diffuse large b cell lymphoma
  • electronic health record
  • hodgkin lymphoma
  • big data
  • free survival
  • stem cells
  • machine learning
  • mesenchymal stem cells
  • artificial intelligence
  • deep learning